New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC) Grant
Funding Amount
US $75,000 - US $250,000
Deadline
Deadline not published
Grant Type
Foundation
Overview
The grant titled 'New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)' by Pfizer aims to support independent medical education focused on innovative therapies such as EZH2 inhibition. It targets increasing awareness among healthcare professionals regarding the mechanisms of action of emerging therapies, the role of novel mechanisms in disease progression, and the need for novel therapies in mCRPC. This initiative underscores Pfizer's commitment to improving patient outcomes in oncology.
Pfizer Inc.
Pfizer's purpose is breakthroughs that change patients’ lives. It was Charles Pfizer’s vision at the beginning and it holds true today.
New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Overview
This competitive grant program seeks to support independent medical education addressing the new mechanisms in mCRPC including EZH2 inhibition and its possible role in prostate cancer and the continued unmet need for novel therapies in mCRPC.
Project Types and Area of Interest
Projects that will be considered for Pfizer support will focus on increasing healthcare professional awareness and understanding in the following areas:
differentiated mechanism of action (MOA) of emerging therapies including EZH2 inhibition and its possible role in prostate cancerEZH2 and other novel mechanisms of disease (MOD) and their role in prostate cancer progressionthe investigational thesis of how concomitant EZH2 and AR inhibition may suppress prostate cancer while delaying or overcoming ARPi resistancethe continued unmet need for novel therapies in mCRPC
mCRPC therapies beyond chemotherapy
ongoing clinical trials that may be an option for patients today
What The Pfizer Foundation Inc actually gave
Source: IRS Form 990-PF, 2024
- Grants in 2024
- 9,306
- Total given
- $23.24M
Focus Areas & Funding Uses
Fields of Work
- Science research
- Healthcare
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Bronchoscopy Research Grant
Intuitive Foundation
Amount
Up to US $75,000
Deadline
January 4, 2027
Listed date — confirm with the funder
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma Grant
The Pfizer Foundation Inc
Amount
US $50,000 - US $200,000
Deadline
Deadline not published
Pfizer Clostridioides difficile (C. difficile) Research Collaboration Grant
The Pfizer Foundation Inc
Amount
Up to US $500,000
Deadline
Deadline not published
Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC) Grant
The Pfizer Foundation Inc
Amount
US $150,000 - US $250,000
Deadline
Deadline not published
RD Global Monitoring anti-TFPI RES
The Pfizer Foundation Inc
Amount
Varies
Deadline
Deadline not published
Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $250,000
Deadline
January 7, 2027
Ready to apply for New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC) Grant?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC) Grant. Now let's win it.